Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease.
During a randomized, double-blind, crossover, placebo-controlled clinical trial of isoniazid (plus pyridoxine) in Huntington's disease (HD), amino acids and related amino compounds were measured in both cerebrospinal fluid (CSF) and plasma utilizing a newly developed high-performance liquid chromatography ion-exchange/fluorometric assay method. Results showed that isoniazid (plus pyridoxine) significantly elevated the mean (+/- S.E.M.) levels of gamma-aminobutyric acid, aspartate, asparagine, homocarnosine, ornithine, histidine, alpha-aminobutyric acid, isoleucine, leucine and alanine in CSF and the levels of beta-alanine in both CSF and plasma. These alterations can be traced to inhibition of decarboxylation and transamination reactions requiring the cofactor pyridoxal phosphate and may be related to the observed equivocal clinical response in the HD patients. The differential influence of isoniazid on plasma and CSF amino acid profiles suggests that alterations of CNS amino acid metabolism may be reflected in CSF, and that isoniazid-induced alterations of amino acid metabolism in the CNS differ from those in the periphery.
D000328:Adult; D000596:Amino Acids / Q000097:blood / Q000134:cerebrospinal fluid*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006639:Histidine / Q000097:blood / Q000134:cerebrospinal fluid; D006801:Humans; D006816:Huntington Disease / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D007538:Isoniazid / Q000627:therapeutic use*; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000097:blood / Q000134:cerebrospinal fluid*; D011736:Pyridoxine / Q000627:therapeutic use; D011897:Random Allocation; D005680:gamma-Aminobutyric Acid / Q000097:blood / Q000134:cerebrospinal fluid
D000596:Amino Acids; D018377:Neurotransmitter Agents; D006639:Histidine; D005680:gamma-Aminobutyric Acid; D011736:Pyridoxine; D007538:Isoniazid